Anlon Healthcare Restricted is developing with its Preliminary Public Providing (IPO) to lift capital for working capital, capital expenditure necessities, and to cut back debt. The IPO contains fully a contemporary difficulty of 1.33 crore fairness shares. The entire provide dimension aggregates as much as Rs. 121.03 crore.
The IPO opens on August 26, 2025, and closes on August 29, 2025. The shares will likely be listed on NSE and BSE on Wednesday, September 3, 2025. Right here’s all the things you want to know.
GMP of Anlon Healthcare IPO
As of August 21, 2025, the GMP for Anlon Healthcare IPO has not but began. Traders ought to watch for updates as GMP info will likely be supplied as soon as obtainable..
Overview of Anlon Healthcare Restricted
Anlon Healthcare Restricted, included in 2013, is a chemical manufacturing firm targeted on producing pharma intermediates and lively pharmaceutical substances (APIs). These merchandise are extensively utilized in medicines, nutraceuticals, private care, and veterinary well being merchandise.
The corporate manufactures high-purity merchandise following world requirements like IP, BP, EP, JP, and USP. It additionally supplies customized chemical manufacturing, assembly particular buyer wants by exceeding purity requirements. Anlon Healthcare has acquired DMF approvals from world authorities, together with ANVISA, NMPA, and PMDA. It has additionally filed 21 DMFs and is making ready to file extra for key merchandise.
At present, the corporate has a portfolio of 65 commercialized merchandise, 28 within the pilot stage, and 49 beneath laboratory testing. Supported by 4 labs and a talented 34-member science group, Anlon ensures constant high quality. As of January 2025, the corporate employed 105 employees and eight contract staff.
Promoters of Anlon Healthcare Restricted
The promoters of Anlon Healthcare Restricted are Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia. They bring about years of experience in medical tools distribution and enterprise operations.
Lead Managers of Anlon Healthcare Restricted IPO
Interactive Monetary Companies Restricted is the only real E book Working Lead Supervisor of the IPO. KFin Applied sciences Restricted is appearing because the registrar for the difficulty.
Targets of the IPO Supply
Anlon Healthcare Restricted plans to make the most of the IPO proceeds for 4 main functions. The corporate will allocate Rs. 30.72 crore in direction of funding capital expenditure necessities for its proposed enlargement initiatives.
Moreover, Rs. 5 crore will likely be used to repay or prepay sure excellent secured borrowings availed by time period loans. An additional Rs. 43.15 crore will likely be directed in direction of assembly the corporate’s working capital necessities to help operations. The remaining funds will likely be utilized for common company functions, strengthening the corporate’s general monetary flexibility and strategic progress initiatives.
Monetary Evaluation of Anlon Healthcare Restricted
Anlon Healthcare Restricted’s income has elevated from Rs. 66.58 crore in FY24 to Rs. 120.29 crore in FY25, which represents a progress of 80.67 %. The web revenue has elevated by 65.70 %, from Rs. 9.66 crore in FY24 to Rs. 20.52 crore in FY25.
The essential earnings per share decreased by 4.49 % and stood at Rs. 6.38 in FY25 as towards Rs. 6.68 recorded in FY24. By way of return ratios, the corporate’s ROCE and ROE stand at 21.93 % and 40.45 %, respectively. Patel Retail Restricted’s debt-to-equity ratio is 0.73x.
Anlon Healthcare Restricted vs Friends
Anlon Healthcare Restricted reported an EPS of Rs. 6.38 and a RoNW of 25.51 %. Compared, Kronox Lab Sciences Restricted’s EPS of Rs. 6.91, and its RoNW of 28.26 %. AMI Organics Restricted reported Rs. 19.81 EPS, and a RoNW of 12.15 %, and Supriya Lifeciences Restricted reported Rs. 23.35 EPS, and a RoNW of 18.86 %.
Anlon Healthcare Restricted’s web asset worth per share is Rs. 20.18, in comparison with Rs. 24.28 for Kronox Lab Sciences Restricted, Rs. 161.24 for AMI Organics Restricted, and Rs. 123.85 for Supriya Lifeciences Restricted.
Strengths of Anlon Healthcare Restricted
- Sturdy promoter expertise ensures sturdy management and long-term firm imaginative and prescient.
- Large product portfolio caters to various healthcare and pharmaceutical business calls for.
- Dedication to high quality requirements builds belief with purchasers and regulators.
- Strategic location in Gujarat supplies logistical and operational benefits.
- Concentrate on compliance strengthens model popularity and enterprise sustainability.
Weaknesses of Anlon Healthcare Restricted
- Excessive dependency on market demand fluctuations will increase enterprise threat publicity.
- Comparatively small scale limits bargaining energy with bigger opponents.
- Important working capital necessities pressure short-term liquidity assets.
- Enterprise focus in healthcare exposes the corporate to sector-specific dangers.
- First-time IPO itemizing poses uncertainty in post-listing share efficiency.
Conclusion
Anlon Healthcare Restricted’s IPO gives traders publicity to India’s rising healthcare and pharmaceutical sector. Its skilled promoters, strategic operations, and monetary progress spotlight robust potential. Traders ought to evaluate financials, strengths, weaknesses, and sector dynamics earlier than subscribing to the IPO.
Written By – Nikhil Naik
Disclaimer
The views and funding ideas expressed by funding specialists/broking homes/ranking businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Traders should due to this fact train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the creator should not accountable for any losses prompted because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
